Format

Send to

Choose Destination
Surg Oncol Clin N Am. 2013 Apr;22(2):329-43. doi: 10.1016/j.soc.2012.12.002. Epub 2013 Jan 9.

Multidisciplinary management of small cell lung cancer.

Author information

1
Department of Hematology/Oncology, Yale Cancer Center, New Haven, CT 06520, USA.

Abstract

The standard treatment of limited-stage small cell lung cancer (SCLC) is concurrent cisplatin and etoposide with thoracic radiation therapy, whereas treatment of extensive-stage disease is typically chemotherapy alone with a platinum compound plus etoposide. Surgical resection of early disease is generally reserved for patients with small, node-negative disease. Prophylactic cranial irradiation reduces the development of brain metastases and prolongs survival in patients with both limited-stage and extensive-stage disease who have responded to chemotherapy. Further understanding of the molecular underpinnings of SCLC is necessary to develop better treatment options and improve outcomes for patients.

PMID:
23453338
DOI:
10.1016/j.soc.2012.12.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center